Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.

Dasanu CA, Alexandrescu DT, Dutcher J.

South Med J. 2007 Mar;100(3):328-30. Erratum in: South Med J. 2007 May;100(5):485.

PMID:
17396743
2.

Acute pancreatitis associated with sorafenib.

Li M, Srinivas S.

South Med J. 2007 Sep;100(9):909-11.

PMID:
17902294
3.

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK.

Br J Dermatol. 2009 Nov;161(5):1045-51. doi: 10.1111/j.1365-2133.2009.09290.x. Epub 2009 May 5.

PMID:
19558553
4.

Sorafenib induced eruptive melanocytic lesions.

Uhlenhake EE, Watson AC, Aronson P.

Dermatol Online J. 2013 May 15;19(5):18184.

5.

Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.

Nakano K, Komatsu K, Kubo T, Natsui S, Nukui A, Kurokawa S, Kobayashi M, Morita T.

Jpn J Clin Oncol. 2013 Oct;43(10):1023-9. doi: 10.1093/jjco/hyt110. Epub 2013 Aug 15.

6.

Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.

Ikeda M, Fujita T, Mii S, Tanabe K, Tabata K, Matsumoto K, Satoh T, Iwamura M.

Jpn J Clin Oncol. 2012 Sep;42(9):820-4. doi: 10.1093/jjco/hys103. Epub 2012 Jul 10.

7.

Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib.

Sahai S, Swick BL.

Int J Dermatol. 2010 Oct;49(10):1203-6. doi: 10.1111/j.1365-4632.2010.04606.x.

PMID:
20883411
8.

Managing adverse events associated with sorafenib in renal cell carcinoma.

Edmonds K, Spencer-Shaw A.

Br J Nurs. 2010 Jan 14-27;19(1):58-60.

PMID:
20081715
9.

Sorafenib-induced erythema multiforme: three cases.

Namba M, Tsunemi Y, Kawashima M.

Eur J Dermatol. 2011 Nov-Dec;21(6):1015-6. doi: 10.1684/ejd.2011.1535. Review. No abstract available.

PMID:
21926043
10.

Sorafenib.

Hasskarl J.

Recent Results Cancer Res. 2010;184:61-70. doi: 10.1007/978-3-642-01222-8_5. Review.

PMID:
20072831
11.

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.

Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, Kuo TT, Hsieh JJ, Chang JW.

Br J Dermatol. 2008 Mar;158(3):592-6. Epub 2007 Dec 6.

PMID:
18070211
12.

[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].

Bolenz C, Trojan L, Honeck P, Schöppler G, Herrmann E, Alken P, Michel MS, Häcker A.

Aktuelle Urol. 2009 Jan;40(1):31-6. doi: 10.1055/s-2008-1038176. Epub 2009 Jan 28. German.

PMID:
19177319
13.

Sorafenib-induced eruptive melanocytic lesions.

Kong HH, Sibaud V, Chanco Turner ML, Fojo T, Hornyak TJ, Chevreau C.

Arch Dermatol. 2008 Jun;144(6):820-2. doi: 10.1001/archderm.144.6.820. No abstract available.

14.

Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma.

Sil A, Das NK.

Indian J Pharmacol. 2014 May-Jun;46(3):334-6. doi: 10.4103/0253-7613.132189.

15.

Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.

Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA.

J Clin Oncol. 2008 Aug 20;26(24):4047-8. doi: 10.1200/JCO.2008.18.3525. No abstract available.

16.

[Cutaneous side effects of sorafenib and sunitinib].

Autier J, Mateus C, Wechsler J, Spatz A, Robert C.

Ann Dermatol Venereol. 2008 Feb;135(2):148-53; quiz 147, 154. doi: 10.1016/j.annder.2007.12.006. Epub 2008 Feb 13. Review. French. No abstract available.

PMID:
18342102
17.

[Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].

Xie XD, Piao Y, Liu ZZ.

Zhonghua Zhong Liu Za Zhi. 2009 Sep;31(9):714-5. Chinese. No abstract available.

PMID:
20021872
18.

Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.

Beldner M, Jacobson M, Burges GE, Dewaay D, Maize JC Jr, Chaudhary UB.

Oncologist. 2007 Oct;12(10):1178-82.

19.

Sorafenib-induced palmoplantar hyperkeratosis.

Lountzis NI, Maroon MS.

J Drugs Dermatol. 2008 Jun;7(6):588-9.

PMID:
18561593
20.

Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?

Sibaud V, Delord JP, Chevreau C.

Target Oncol. 2009 Dec;4(4):307-10. doi: 10.1007/s11523-009-0127-8. Epub 2009 Nov 7.

PMID:
19894099
Items per page

Supplemental Content

Write to the Help Desk